Gourab Datta1, Ines R Violante1, Gregory Scott1, Karl Zimmerman1, Andre Santos-Ribeiro1, Eugenii A Rabiner2, Roger N Gunn3, Omar Malik1, Olga Ciccarelli4, Richard Nicholas1, Paul M Matthews1. 1. Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK. 2. Imanova Ltd, Imperial College London, London, UK/Centre for Neuroimaging Sciences, King's College London, London, UK. 3. Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK/manova Ltd, Imperial College London, London, UK. 4. Queen Square Multiple Sclerosis Centre, Institute of Neurology, University College London, London, UK.
Abstract
BACKGROUND: Multiple sclerosis (MS) is characterised by a diffuse inflammatory response mediated by microglia and astrocytes. Brain translocator protein (TSPO) positron-emission tomography (PET) and [myo-inositol] magnetic resonance spectroscopy (MRS) were used together to assess this. OBJECTIVE: To explore the in vivo relationships between MRS and PET [11C]PBR28 in MS over a range of brain inflammatory burden. METHODS: A total of 23 patients were studied. TSPO PET imaging with [11C]PBR28, single voxel MRS and conventional magnetic resonance imaging (MRI) sequences were undertaken. Disability was assessed by Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC). RESULTS: [11C]PBR28 uptake and [ myo-inositol] were not associated. When the whole cohort was stratified by higher [11C]PBR28 inflammatory burden, [ myo-inositol] was positively correlated to [11C]PBR28 uptake (Spearman's ρ = 0.685, p = 0.014). Moderate correlations were found between [11C]PBR28 uptake and both MRS creatine normalised N-acetyl aspartate (NAA) concentration and grey matter volume. MSFC was correlated with grey matter volume (ρ = 0.535, p = 0.009). There were no associations between other imaging or clinical measures. CONCLUSION: MRS [ myo-inositol] and PET [11C]PBR28 measure independent inflammatory processes which may be more commonly found together with more severe inflammatory disease. Microglial activation measured by [11C]PBR28 uptake was associated with loss of neuronal integrity and grey matter atrophy.
BACKGROUND: Multiple sclerosis (MS) is characterised by a diffuse inflammatory response mediated by microglia and astrocytes. Brain translocator protein (TSPO) positron-emission tomography (PET) and [myo-inositol] magnetic resonance spectroscopy (MRS) were used together to assess this. OBJECTIVE: To explore the in vivo relationships between MRS and PET [11C]PBR28 in MS over a range of brain inflammatory burden. METHODS: A total of 23 patients were studied. TSPO PET imaging with [11C]PBR28, single voxel MRS and conventional magnetic resonance imaging (MRI) sequences were undertaken. Disability was assessed by Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC). RESULTS: [11C]PBR28 uptake and [ myo-inositol] were not associated. When the whole cohort was stratified by higher [11C]PBR28 inflammatory burden, [ myo-inositol] was positively correlated to [11C]PBR28 uptake (Spearman's ρ = 0.685, p = 0.014). Moderate correlations were found between [11C]PBR28 uptake and both MRS creatine normalised N-acetyl aspartate (NAA) concentration and grey matter volume. MSFC was correlated with grey matter volume (ρ = 0.535, p = 0.009). There were no associations between other imaging or clinical measures. CONCLUSION: MRS [ myo-inositol] and PET [11C]PBR28 measure independent inflammatory processes which may be more commonly found together with more severe inflammatory disease. Microglial activation measured by [11C]PBR28 uptake was associated with loss of neuronal integrity and grey matter atrophy.
Authors: P Sarchielli; O Presciutti; G P Pelliccioli; R Tarducci; G Gobbi; P Chiarini; A Alberti; F Vicinanza; V Gallai Journal: Brain Date: 1999-03 Impact factor: 13.501
Authors: Stephen M Smith; Yongyue Zhang; Mark Jenkinson; Jacqueline Chen; P M Matthews; Antonio Federico; Nicola De Stefano Journal: Neuroimage Date: 2002-09 Impact factor: 6.556
Authors: N De Stefano; M Filippi; D Miller; P J Pouwels; A Rovira; A Gass; C Enzinger; P M Matthews; D L Arnold Journal: Neurology Date: 2007-11-13 Impact factor: 9.910
Authors: J Versijpt; J C Debruyne; K J Van Laere; F De Vos; J Keppens; K Strijckmans; E Achten; G Slegers; R A Dierckx; J Korf; J L De Reuck Journal: Mult Scler Date: 2005-04 Impact factor: 6.312
Authors: B Audoin; D Ibarrola; I Malikova; E Soulier; S Confort-Gouny; M V Au Duong; F Reuter; P Viout; A Ali-Chérif; P J Cozzone; J Pelletier; J P Ranjeva Journal: Mult Scler Date: 2007-01 Impact factor: 6.312
Authors: M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee Journal: Neuropathol Appl Neurobiol Date: 2008-12-11 Impact factor: 8.090
Authors: P A Brex; G J Parker; S M Leary; P D Molyneux; G J Barker; C A Davie; A J Thompson; D H Miller Journal: J Neurol Neurosurg Psychiatry Date: 2000-05 Impact factor: 10.154
Authors: P Kapeller; M A McLean; C M Griffin; D Chard; G J Parker; G J Barker; A J Thompson; D H Miller Journal: J Neurol Date: 2001-02 Impact factor: 4.849
Authors: R B Banati; J Newcombe; R N Gunn; A Cagnin; F Turkheimer; F Heppner; G Price; F Wegner; G Giovannoni; D H Miller; G D Perkin; T Smith; A K Hewson; G Bydder; G W Kreutzberg; T Jones; M L Cuzner; R Myers Journal: Brain Date: 2000-11 Impact factor: 13.501
Authors: Valerie L Jewells; Hong Yuan; Joseph R Merrill; Jonathan E Frank; Akhil Patel; Stephanie M Cohen; Ben Giglio; Nana Nikolaishvili Feinberg; Glenn K Matsushima; Zibo Li Journal: Diagnostics (Basel) Date: 2021-04-27
Authors: Maria Yanez Lopez; Marie-Christine Pardon; Kerstin Baiker; Malcolm Prior; Ding Yuchun; Alessandra Agostini; Li Bai; Dorothee P Auer; Henryk M Faas Journal: PLoS One Date: 2019-02-21 Impact factor: 3.240
Authors: Christine Ghadery; Laura A Best; Nicola Pavese; Yen Foung Tai; Antonio P Strafella Journal: Curr Neurol Neurosci Rep Date: 2019-05-28 Impact factor: 5.081